Internal Medicine, Hematology & Oncology · Orlando, FL
NPI
1760686059
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
922 Lucerne Ter
Orlando, FL, 32806
Phone (407) 426-8660
Groups this clinician bills Medicare through
Medicare paid, 2024
$310K
17,001 services
Medicare patients, 2024
448
Average age 74
Drug cost, 2024
$4.3M
1,333 prescriptions
Company payments, 2025
$6,792
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kalpesh B Barot was code 99232 (hospital e&m - subsequent), 2,019 times for 211 patients. In total Kalpesh B Barot billed 17,001 services in 50 codes, and Medicare paid $310K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-02-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,019 | 211 | $61.41 | $124K |
| 88185 Surgical Pathology Examination | Office | 1,422 | 50 | $17.32 | $25K |
| 99214 Office E&M - Established | Office | 763 | 172 | $90.78 | $69K |
| 36415 Venipuncture Blood Collection | Office | 683 | 154 | $8.65 | $5,908 |
| 85025 Blood Count | Office | 633 | 150 | $7.61 | $4,817 |
| 99233 Hospital E&M - Subsequent | Facility | 271 | 80 | $92.25 | $25K |
| 96372 Injection Administration | Office | 218 | 66 | $9.89 | $2,155 |
| 99223 Hospital E&M - Initial | Facility | 170 | 158 | $133.88 | $23K |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 144 | 59 | $0.92 | $133 |
| 99213 Office E&M - Established | Office | 96 | 57 | $64.20 | $6,163 |
| 88189 Surgical Pathology Examination | Office | 51 | 51 | $63.77 | $3,252 |
| 88184 Surgical Pathology Examination | Office | 50 | 50 | $53.87 | $2,693 |
| 99231 Hospital E&M - Subsequent | Facility | 36 | 12 | $38.23 | $1,376 |
| 99205 Office E&M - New | Office | 31 | 31 | $158.26 | $4,906 |
By year: 2022 $300K for 10,086 services; 2023 $331K for 16,341 services; 2024 $310K for 17,001 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 1,422 | 50 | $17.32 | $25K |
| 36415 Venipuncture Blood Collection | 683 | 154 | $8.65 | $5,908 |
| 85025 Blood Count | 633 | 150 | $7.61 | $4,817 |
| 88189 Surgical Pathology Examination | 51 | 51 | $63.77 | $3,252 |
| 88184 Surgical Pathology Examination | 50 | 50 | $53.87 | $2,693 |
Medicare prescription drug claims, 2024
In 2024, the drug Kalpesh B Barot prescribed most often to Medicare patients was Eliquis (Apixaban), with 272 prescriptions and refills. In total Kalpesh B Barot wrote 1,333 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 272 | 468 | 61 | $259K |
| Retacrit Epoetin Alfa-Epbx | 111 | 111 | 24 | $95K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 58 | 58 | Under 11 | $2,860 |
| Procrit Epoetin Alfa | 58 | 58 | 12 | $155K |
| Anastrozole Generic | 50 | 148 | 14 | $1,464 |
| Inqovi Decitabine/Cedazuridine | 45 | 45 | Under 11 | $357K |
| Ondansetron Hcl Generic | 44 | 44 | 16 | $966 |
| Xarelto Rivaroxaban | 42 | 84 | 12 | $46K |
| Xtandi Enzalutamide | 38 | 38 | Under 11 | $538K |
| Hydroxyurea Generic | 35 | 78 | Under 11 | $1,980 |
| Imbruvica Ibrutinib | 33 | 33 | Under 11 | $508K |
| Oxycodone Hcl Generic | 29 | 29 | Under 11 | $509 |
| Warfarin Sodium Generic | 26 | 77 | Under 11 | $160 |
| Jakafi Ruxolitinib Phosphate | 25 | 25 | Under 11 | $405K |
| Lenalidomide Generic | 22 | 22 | Under 11 | $302K |
Brand drugs: 760 claims; generic drugs: 573 claims; opioid claims: 145.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kalpesh B Barot $6,792 ($6,792 in general payments such as food, travel and fees) from 37 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $3,930.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 14 | $3,930 |
| Daiichi Sankyo Inc. 4568.T | 5 | $721 |
| Merck Sharp & Dohme LLC MRK | 8 | $188 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $174 |
| Cardinal Health 110 LLC | 1 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $124 |
| Celgene Corporation BMY | 4 | $120 |
| Pfizer Inc. PFE | 6 | $116 |
| Eisai Inc. 4523.T | 5 | $115 |
| Incyte Corporation INCY | 5 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.